UK pharma group calls for regulatory reform

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is being urged to rebuild its standing following an internal restructuring, as the regulator finds its feet in a post-Brexit environment.

A new report from the Association of the British Pharmaceutical Industry (ABPI) lays out a roadmap for the agency to: “regain its world-class reputation,” calling for more resources and the adoption of flexible licensing routes.

Richard Torbett, chief executive of the ABPI, said: “This report sets out a clear roadmap for the MHRA’s incoming leadership to ensure the UK can operate as a leading authority that supports the development of new medicines and can safely and swiftly bring new innovations and treatments to patients.”